Drug Trial Radar · NCT02322333
MLD10 in the Prevention of Migraine in Adults
Last checked: Nov 19, 2026Latest source record: Oct 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
157
Actual
Start
Mar 2015
Primary completion
Jun 2017
Study completion Jun 2017
Sponsor
- Lead sponsor
- Pharmalyte Solutions LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Clinvest
- First posted
- Dec 23, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a double-blind, placebo-controlled, randomized, multi-center study. Subjects agreeing to participate in the study and meet the entry criteria assessed at the screening visit, will begin a 28 day baseline period to confirm their diagnosis, as well as establish baseline migraine characteristics. During this baseline period, subjects will continue treating their migraines as usual, simply recording the information in a daily headache diary. Subjects who, after completing the baseline, continue to meet entrance criteria will be eligible to enter into the treatment phase and be randomized according to the Clinvest generated randomization schedule. Approximately 142 subjects (71 subjects per arm) will be randomized and enter the treatment phase receiving MLD10 or placebo in a 1:1 design at 6 United States sites. Diary assessments will collect study medication adherence, pain severity, headache symptoms, acute medication usage, and unusual symptoms. Serum samples will be collected and analyzed for ionized magnesium, electrolytes, and creatinine.
Conditions
- Migraine
Interventions
MLD10Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Migraine Headache DaysTime frame: Day 1(Screening) - Day 116 (Visit 5 End of Study)
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
The Research Center of Southern California
Carlsbad, California
San Francisco Clinical Research Center
San Francisco, California
Physician Associates of Florida Research Department
Oviedo, Florida
Dr. B. Abraham, P.C.
Snellville, Georgia
Westside Family Medical Center, P.C.
Kalamazoo, Michigan
StudyMetrix Research
City of Saint Peters, Missouri
Clinvest Research, LLC
Springfield, Missouri
Baptist Memorial Hospital
Memphis, Tennessee
Nashville Neuroscience Group
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.